130 related articles for article (PubMed ID: 25579575)
1. An in silico approach for identification of novel inhibitors as a potential therapeutics targeting HIV-1 viral infectivity factor.
Sinha C; Nischal A; Bandaru S; Kasera P; Rajput A; Nayarisseri A; Khattri S
Curr Top Med Chem; 2015; 15(1):65-72. PubMed ID: 25579575
[TBL] [Abstract][Full Text] [Related]
2. Molecular docking analysis of RN18 and VEC5 in A3G-Vif inhibition.
Sinha C; Nischal A; Pant KK; Bandaru S; Nayarisseri A; Khattri S
Bioinformation; 2014; 10(10):611-6. PubMed ID: 25489169
[TBL] [Abstract][Full Text] [Related]
3. The Structural Interface between HIV-1 Vif and Human APOBEC3H.
Ooms M; Letko M; Simon V
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031368
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication.
Ali A; Wang J; Nathans RS; Cao H; Sharova N; Stevenson M; Rana TM
ChemMedChem; 2012 Jul; 7(7):1217-29. PubMed ID: 22555953
[TBL] [Abstract][Full Text] [Related]
5. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
6. Lead optimization to improve the antiviral potency of 2-aminobenzamide derivatives targeting HIV-1 Vif-A3G axis.
Zhong X; Luo R; Yan G; Ran K; Shan H; Yang J; Liu Y; Yu S; Pu C; Zheng Y; Li R
Eur J Med Chem; 2021 Nov; 224():113680. PubMed ID: 34245947
[TBL] [Abstract][Full Text] [Related]
7. Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface.
Letko M; Booiman T; Kootstra N; Simon V; Ooms M
Cell Rep; 2015 Dec; 13(9):1789-99. PubMed ID: 26628364
[TBL] [Abstract][Full Text] [Related]
8. 1,2,3-Triazoles as Amide Bioisosteres: Discovery of a New Class of Potent HIV-1 Vif Antagonists.
Mohammed I; Kummetha IR; Singh G; Sharova N; Lichinchi G; Dang J; Stevenson M; Rana TM
J Med Chem; 2016 Aug; 59(16):7677-82. PubMed ID: 27509004
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Conserved Interface of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Vifs with Cullin 5.
Gu Q; Zhang Z; Gertzen CGW; Häussinger D; Gohlke H; Münk C
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263270
[TBL] [Abstract][Full Text] [Related]
10. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of indole derivatives as Vif inhibitors.
Pu C; Luo RH; Zhang M; Hou X; Yan G; Luo J; Zheng YT; Li R
Bioorg Med Chem Lett; 2017 Sep; 27(17):4150-4155. PubMed ID: 28754362
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
13. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.
Zhang S; Zhong L; Chen B; Pan T; Zhang X; Liang L; Li Q; Zhang Z; Chen H; Zhou J; Luo H; Zhang H; Bai C
Antiviral Res; 2015 Oct; 122():20-7. PubMed ID: 26241003
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological evaluation and molecular docking study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif antagonists.
Zhou M; Luo RH; Hou XY; Wang RR; Yan GY; Chen H; Zhang RH; Shi JY; Zheng YT; Li R; Wei YQ
Eur J Med Chem; 2017 Mar; 129():310-324. PubMed ID: 28235704
[TBL] [Abstract][Full Text] [Related]
15. Viral infectivity factor: a novel therapeutic strategy to block HIV-1 replication.
Yang G; Xiong X
Mini Rev Med Chem; 2013 Jun; 13(7):1047-55. PubMed ID: 23621690
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of 2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif inhibitors.
Zhang RH; Wang S; Luo RH; Zhou M; Zhang H; Xu GB; Zhao YL; Li YJ; Wang YL; Yan G; Liao SG; Zheng YT; Li R
Bioorg Med Chem Lett; 2019 Dec; 29(24):126638. PubMed ID: 31685340
[TBL] [Abstract][Full Text] [Related]
17. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
18. An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G.
Ejima T; Hirota M; Mizukami T; Otsuka M; Fujita M
Int J Mol Med; 2011 Oct; 28(4):613-6. PubMed ID: 21725586
[TBL] [Abstract][Full Text] [Related]
19. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
[TBL] [Abstract][Full Text] [Related]
20. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
